11:30 AM EST - Trillium Therapeutics Inc. : announced that it has priced an underwritten public offering of 1,522,395 common shares and 1,077,605 non-voting convertible preferred shares at a price of $19.50 U.S. per share for aggregate gross proceeds of $50.7 million U.S. before deducting underwriting discounts and commissions and other offering expenses. Trillium Therapeutics Inc.
shares T.TR are trading up $3.85 at $29.60.
